CA2938057A1 - Use of paricalcitol in the treatment of inflammatory anaemia - Google Patents

Use of paricalcitol in the treatment of inflammatory anaemia Download PDF

Info

Publication number
CA2938057A1
CA2938057A1 CA2938057A CA2938057A CA2938057A1 CA 2938057 A1 CA2938057 A1 CA 2938057A1 CA 2938057 A CA2938057 A CA 2938057A CA 2938057 A CA2938057 A CA 2938057A CA 2938057 A1 CA2938057 A1 CA 2938057A1
Authority
CA
Canada
Prior art keywords
paricalcitol
patients
levels
esa
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2938057A
Other languages
English (en)
French (fr)
Inventor
Miguel Giovanni Uriol Rivera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2938057A1 publication Critical patent/CA2938057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2938057A 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia Abandoned CA2938057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430177 2014-02-11
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (1)

Publication Number Publication Date
CA2938057A1 true CA2938057A1 (en) 2015-08-20

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938057A Abandoned CA2938057A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583539A2 (en) 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Also Published As

Publication number Publication date
ES2472040B1 (es) 2015-07-01
AU2015217956B2 (en) 2019-04-04
CN106061498B (zh) 2019-12-06
DK3104872T3 (da) 2019-06-17
AR099330A1 (es) 2016-07-13
ES2472040R1 (es) 2014-09-18
WO2015121022A1 (en) 2015-08-20
ES2472040A2 (es) 2014-06-27
EP3104872A1 (en) 2016-12-21
US20160367571A1 (en) 2016-12-22
EP3104872B1 (en) 2019-03-13
MX2016010104A (es) 2017-01-06
MX365096B (es) 2019-05-22
IL247207A0 (en) 2016-09-29
PT3104872T (pt) 2019-06-11
ES2728158T3 (es) 2019-10-22
RU2016131412A (ru) 2018-03-15
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
CN106061498A (zh) 2016-10-26
JP2017512753A (ja) 2017-05-25
KR20160113664A (ko) 2016-09-30
AU2015217956A1 (en) 2016-08-25
UY35989A (es) 2015-03-27

Similar Documents

Publication Publication Date Title
Haroon et al. A novel role for erythropoietin during fibrin-induced wound-healing response
Wright et al. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus
Drüeke et al. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients
Milovanova et al. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b–4 stages chronic кidney disease patients: a randomized pilot study
Huang et al. Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: a novel mutation
JP2016179994A (ja) イネカルシトールの新しい治療的使用
Luo et al. Impact of tacrolimus on bone metabolism after kidney transplantation
AU2015217956B2 (en) Use of paricalcitol in the treatment of inflammatory anaemia
Akizawa et al. Long-term effect of 1, 25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study
Sethi et al. Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism
Menon et al. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: a review of the role of iron
Johnson et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
Namgung et al. Perinatal calcium and phosphorus metabolism
TW202227046A (zh) 三苯基鈣敏感性化合物之治療方法
Tidblad et al. Metabolic effects of growth hormone treatment in short prepubertal children: a double-blinded randomized clinical trial
Rodelo-Haad et al. Iron repletion and FGF23 regulation. A potentially dangerous combination
Mitsopoulos et al. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism
CA2759815C (en) Method of treating frailty
Bashardoust et al. Treatment effect of ergocalciferol on bone metabolism indexes and parathyroid hormone in hemodialysis patients
US20170102398A1 (en) Predicting and reducing cognitive decline based on gsk-3 levels
Rubin et al. TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
Ziólkowska Minimizing bone abnormalities in children with renal failure
Abu-Hamdan et al. Zinc tolerance test in uremia: effect of calcitriol supplementation.
Lee Characterizing the Development of Secondary Hyperparathyroidism and Vitamin D Resistance in Experimental Chronic Kidney Disease
Patel et al. and Metabolic Aging

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191119

FZDE Discontinued

Effective date: 20220406